Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 17/20 | 0.91 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.91 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL5973522 | 1.00 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7831398 | 1.00 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL6743637 | 1.00 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5974480 | 1.00 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL1268401 | 1.00 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL1130855 | 1.00 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5973509 | 1.00 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL1268399 | 1.00 | FDPS (0.91) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL6756474 | 0.98 | FDPS (0.87) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7751950 | 0.98 | FDPS (0.87) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116139333-B | Carbon fiber reinforced polyether-ether-ketone composite material and preparation method and application thereof | 吉林大学 | 2024-04-12 | — | — | CN | claimed |
| CN-116139333-A | Carbon fiber reinforced polyether-ether-ketone composite material and preparation method and application thereof | 吉林大学 | 2023-05-23 | — | — | CN | claimed |
| US-20220242893-A1 | AMIDE-LINKED CONJUGATE COMPOUNDS AND USES THEREOF | UNIV FRASER SIMON (CA) | 2022-08-04 | — | — | US | claimed |
| US-11312737-B2 | Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2022-04-26 | — | — | US | claimed |
| CN-114306626-A | Allan phosphonic acid modified astragaloside IV PEG-PLGA nano micelle and research on anti-osteoporosis effect thereof | 席焱海 | 2022-04-12 | — | — | CN | claimed |
| US-9592195-B2 | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics | EFFRX PHARMACEUTICALS SA (CH) | 2017-03-14 | — | — | US | claimed |
| US-9593114-B2 | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives | SCIFLUOR LIFE SCIENCES, INC. (US) | 2017-03-14 | — | — | US | claimed |
| US-20160130270-A1 | FLUORINATED 3-(2-OXO-3-(3-ARYLPROPYL)IMIDAZOLIDIN-1-YL)-3-ARYLPROPANOIC ACID DERIVATIVES | FELIQS CORPORATION (JP) | 2016-05-12 | — | — | US | claimed |
| EP-2561877-A1 | A Composition containing a Bisphosphonic Acid in combination with Vitamin D | Mylan Pharmaceuticals ULC (CA) | 2013-02-27 | — | — | EP | claimed |
| EP-1252162-B1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-07-25 | — | — | EP | claimed |
| WO-1999030713-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | claimed |
| WO-1999030709-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | claimed |
| WO-1999031061-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | claimed |
| US-5914099-A | Prevention of tooth loss by the administration of alendronate or its salts | MERCK & CO., INC. (US) | 1999-06-22 | — | — | US | claimed |
| WO-1999004773-A2 | METHOD FOR INHIBITING BONE RESORPTION | MERCK & CO., INC. (US) | 1999-02-04 | — | — | WO | claimed |
| WO-1998031359-A1 | INTEGRIN ANTAGONISTS | MERCK & CO., INC. (US) | 1998-07-23 | — | — | WO | claimed |
| WO-1998014196-A1 | LIQUID ALENDRONATE FORMULATIONS | MERCK & CO., INC. (US) | 1998-04-09 | — | — | WO | claimed |
| EP-0824341-A1 | PREVENTION OF TOOTH LOSS BY THE ADMINISTRATION OF ALENDRONATE OR ITS SALTS | Merck & Co., Inc. (US) | 1998-02-25 | — | — | EP | claimed |
| US-5646134-A | INHIBITING BONE RESORPTION | MERCK & CO., INC. (US) | 1997-07-08 | — | — | US | claimed |
| WO-1996035407-A1 | PREVENTION OF TOOTH LOSS BY THE ADMINISTRATION OF ALENDRONATE OR ITS SALTS | MERCK & CO., INC. (US) | 1996-11-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130270-A1 | FLUORINATED 3-(2-OXO-3-(3-ARYLPROPYL)IMIDAZOLIDIN-1-YL)-3-ARYLPROPANOIC ACID DERIVATIVES | ITGB3, ITGA2, ITGA1 | FDPS 1908/4885PDE3A 2026/4885LMNA 2972/4885 |
| US-11312737-B2 | Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof | PTGER4, ENPP2, GPR4 | FDPS 1484/4885PDE3A 1505/4885LMNA 3845/4885 |
| US-20220242893-A1 | AMIDE-LINKED CONJUGATE COMPOUNDS AND USES THEREOF | AADAC, DNPEP, NAALAD2 | FDPS 769/4885PDE3A 2015/4885LMNA 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.